Hims & Hers Health (HIMS) is a high-conviction play positioned as the primary telehealth provider for the GLP-1 weight-loss market, benefiting from a subscription model that bypasses insurance friction.

Despite the stock doubling recently, it remains undervalued relative to historical prices, and investors should watch for a significant upward revision to 2026 revenue guidance following the Eucalyptus acquisition.

The company is expanding its ecosystem through international growth and the upcoming launch of new peptide treatments this summer, which serve as massive untapped financial tailwinds.

While HIMS is volatile, it represents a major disruption to traditional healthcare by using high-demand medications like Wegovy and Tirzepatide as gateways for long-term customer retention.

For those seeking exposure to the Bitcoin proxy trade, MicroStrategy (MSTR) remains a core high-interest holding despite recent underperformance and price volatility.

Hims & Hers Health, Inc. (HIMS)

The stock is currently experiencing a significant surge, recently up 8% following an upgrade from Barclays. The primary driver is the "GLP-1 frenzy," as the market recognizes the company as a leading telehealth provider for weight-loss medications.

• GLP-1 Market Leadership: HIMS is positioned as "ground zero" for GLP-1 prescriptions. Because most insurance companies do not reimburse these expensive medications, patients are turning to HIMS for accessible, out-of-pocket options.
  • The platform offers a variety of options, including Liraglutide, oral Wegovy, and Tirzepatide (Eli Lilly’s weight loss tool).
  • A key "peak signal" for the company was the recent ability to offer Eli Lilly’s medications on the HIMS app, which functions effectively as a partnership.
• Business Model Advantages:
  • Subscription-Based: Operates on a transparent, Netflix-style subscription model that includes the doctor consultation, the prescription, and follow-ups.
  • No Insurance Friction: Unlike Amazon or traditional providers, HIMS does not accept insurance. This eliminates the administrative burden of reimbursements and allows the company to focus entirely on customer experience.
  • Cross-Selling: The company uses "blockbuster" drugs (ED, Hair Loss, Statins) to bring customers into the ecosystem and then cross-sells for other ailments.
• Financials and Valuation:
  • Despite doubling from February lows, the speaker argues the stock is still "cheap" and trading at a significant discount (approx. 43%) from its prices a year ago.
  • The company is described as a "king of sandbagging," consistently providing conservative guidance that they likely intend to beat.

Takeaways

• Watch for Guidance Updates: Following the closure of the Eucalyptus acquisition, HIMS will likely need to update its 2026 guidance. Current estimates of 19%–28% growth are viewed as too low; internal projections suggest revenue growth could exceed 35% to 50%.
• International Expansion: The Eucalyptus acquisition adds $250M in Annual Recurring Revenue (ARR) and expands the footprint into Japan, Germany, and Australia.
• New Product Vertical (Peptides): Two waves of peptides (such as BPC-157) are expected to launch—one this summer and one early next year. This represents a massive untapped tailwind not currently included in financial guidance.
• Disruption Play: HIMS is viewed as a "Big Tech" disruption of the traditional mom-and-pop doctor’s office for mid-to-low-level health issues.

MicroStrategy (MSTR)

• Mentioned as one of the two most covered stocks on the channel alongside HIMS.
• The speaker noted that MSTR has been "underperforming" recently, leading to increased coverage to address the price action.

Takeaways

• While the focus of this specific discussion was HIMS, the speaker maintains a high level of interest in MSTR as a core portfolio holding, despite recent volatility.

Investment Themes: Telehealth & GLP-1s

The transcript highlights a broader shift in how the general public accesses high-demand medications.

• The "Death of the Mom-and-Pop Doctor": For routine prescriptions and "bread and butter" health issues, patients are moving toward modern UI/UX apps that offer instant access to doctors and transparent pricing.
• GLP-1s as a Gateway: Weight-loss drugs are acting as a massive customer acquisition tool for telehealth platforms. Once a customer is on a subscription for weight loss, the platform can address other issues like HRT (Hormone Replacement Therapy) or heart health.
• Cash-Pay vs. Insurance: There is a growing investment thesis around healthcare companies that bypass the insurance system entirely to avoid regulatory and reimbursement risks.

Takeaways

• Sector Bullishness: The GLP-1 sector is moving from "hope" to "actual results."
• Risk Factors: The speaker notes that HIMS is an "extremely volatile" and "hated stock" by some in the market, often associated with high-risk baskets. Investors should be prepared for significant price swings despite strong fundamentals.